Tracer library / [161Tb]Tb-DOTA-TOC
[161Tb]Tb-DOTA-TOC
Also written as DOTATOC; DOTA-TOC
- Radionuclide
- Tb-161 t½ 9907.2 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 2
What it is
- Compound class
- DOTATOC (somatostatin receptor agonist peptide)
- Target / mechanism
- Somatostatin receptor (SSTR) agonist PMID 34625828
- Clinical application
- Treatment of neuroendocrine neoplasms (preclinical study) PMID 34625828
- Theranostic pair
- [68Ga]Ga-DOTA-TOC
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Modular-Lab PharmTracer Eckert & Ziegler | vendor cassette | none | >85% | 98.2% ± 0.82 | DOTATOC | 37201956 2023 J Nucl Med Modular-Lab PharmTracer fully automated cassette synthesis system (Eckert & Ziegler; Fig. 1A) - a total yield of more than 85% of 161Tb-DOTATOC, in reference to the initial 161Tb activity, was determined |
| — | — | — | — | ≥ 98% | DOTATOC | 34625828 2022 Eur J Nucl Med Mol Imaging |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC.2021 · J Nucl Med · Clinical study
Need this precursor?We can point you to suppliers for [161Tb]Tb-DOTA-TOC, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Compound class inferred from precursor name (not stated outright) -- PMID 34625828: 'DOTATOC'. Stage set/updated at stage 23 from PMID 34625828: 'Based on these preclinical data, [161Tb]Tb-DOTA-LM3 may outperform the clinically employed [177Lu]Lu-DOTATOC for the treatment of patients with NENs.'.